Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
UnicoCell Biomed Co., Ltd. (6794.TW)
Taipei, TW
UnicoCell Biomed Co., Ltd., a Taiwanese enterprise, specializes in the research, development, and application of stem cell-based pharmaceuticals, advanced cell therapy techniques, and regenerative medical solutions. Their flagship product, ELIXCYTE, is presently undergoing Phase 2 clinical trials, targeting both osteoarthritis and chronic kidney disease. Beyond therapeutics, the company also offers UnicoVial, a specialized cryopreservation and drug containment system designed for cell therapy products, and provides a range of related testing services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.49% | -0.49% | -1.68% | -7.99% | +15.21% | -8.71% | +28.01% | -2.50% | -2.50% | -2.50% | -2.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%-5.6% Q4'25: +0.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-20.4% Q4'25: +7.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-401.2% Q4'25: -194.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-432.8% Q4'25: -532.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-74.3% Q4'25: -155.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+2.6% ★ Q4'25: +9.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.57× Q4'25: -0.27× (vs Q4'23)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
31.88M
est: 25.15M (+26.8%)
|
30.10M
est: 33.00M (-8.8%)
|
33.00M
33.00M – 33.00M
+0.0% YoY
|
| EBITDA |
-64.03M
est: -25.15M (-154.6%)
|
-109.73M
est: -33.00M (-232.5%)
|
-33.00M
-33.00M – -33.00M
+0.0% YoY
|
| EBIT |
-91.61M
est: -25.15M (-264.2%)
|
-130.28M
est: -33.00M (-294.8%)
|
-33.00M
-33.00M – -33.00M
+0.0% YoY
|
| Net Income |
-93.07M
est: -91.35M (-1.9%)
|
-114.84M
est: -115.10M (+0.2%)
|
-120.58M
-120.58M – -120.58M
-4.8% YoY
|
| SGA |
34.85M
est: 41.41M (-15.9%)
|
37.62M
est: 54.34M (-30.8%)
|
54.34M
54.34M – 54.34M
+0.0% YoY
|
| EPS |
-1.57
est: -1.50 (-4.7%)
|
-1.89
est: -1.89 (+0.0%)
|
-1.98
-1.98 – -1.98
-4.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yi-Pei Hung | General Manager | 3M | male |
| Lin Chen-Yu | Assistant Vice President | 1M | male |
| Ting Wang | Assistant Vice President | 1M | female |
| Pei-Lin Chen | Chief Financial Officer, Accounting Officer & Corporate Governance Officer | 1M | — |
| Jui-Yu Liu | Chief Internal Auditor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6794.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
